-

Asahi Kasei Adds New Slitting Facility for SUNFORT™ to Meet Growing Demand for Advanced Semiconductor Packaging

TOKYO--(BUSINESS WIRE)--Asahi Kasei, a diversified global company, constructed a new slitting facility for SUNFORT™ dry film photoresist (DFR) at its manufacturing site in Tainan, Taiwan, on July 3. Commercial operations are scheduled to commence this month.

Asahi Kasei has been slitting SUNFORT™ DFR at its Tainan site since 1997. In recent years, demand for advanced semiconductor packaging has grown significantly, driven by AI and the resulting increase in data processing requirements. Accordingly, DFR used in semiconductor packaging must also meet increasingly stringent standards for both quality and supply reliability. In this context, Taiwan is a strategically important location with a strong concentration of semiconductor packaging-related companies, making it essential to have a supply system capable of supplying products rapidly and reliably in close proximity to customers.

Slitting is the process by which master rolls of film are cut into narrower widths in accordance with individual customer requirements. It is a critical process that directly impacts both product quality and supply reliability.

To respond to growing market demand for DFR, Asahi Kasei’s new slitting facility is equipped with state-of-the-art machines and some of the most rigorous cleanroom standards for improved productivity and dependable supply. The facility represents an investment of approximately ¥2 billion (approximately $12 million or €11 million) and will expand capacity by 40% with the potential to double current output.

SUNFORT™ DFR delivers ultra-high resolution with conventional stepper exposure systems and laser direct imaging (LDI) systems, which transfer circuit patterns onto substrates for packaging. This approach improves performance and precision in semiconductor manufacturing back-end processes.

Asahi Kasei’s investment in SUNFORT™ DFR aligns with the company’s positioning of its Electronics Business as a strategic growth driver. In May 2025, Asahi Kasei also launched SUNFORT™ TA, its newest DFR series tailored for advanced semiconductor packaging used in AI servers.

About Asahi Kasei
Asahi Kasei is a diversified global company that contributes to life and living for people around the world. Since its foundation in 1922, with businesses in ammonia and cellulose fiber, Asahi Kasei has consistently grown through proactive portfolio transformation to meet the evolving needs of every age. With 50,000 employees worldwide, the company contributes to sustainability by providing solutions to the world’s challenges across its three business sectors: Healthcare, Homes, and Material. For more information, visit https://www.asahi-kasei.com/.

Contacts

Asahi Kasei America Inc.
Christian OKeefe
christian.okeefe@ak-america.com

Asahi Kasei Europe GmbH
Sebastian Schmidt
sebastian.schmidt@asahi-kasei.eu

Asahi Kasei

TOKYO:3407

Release Summary
Asahi Kasei has constructed a new slitting facility for SUNFORT™ dry film photoresist (DFR) at its manufacturing site in Tainan, Taiwan, on July 3.
Release Versions

Contacts

Asahi Kasei America Inc.
Christian OKeefe
christian.okeefe@ak-america.com

Asahi Kasei Europe GmbH
Sebastian Schmidt
sebastian.schmidt@asahi-kasei.eu

Social Media Profiles
More News From Asahi Kasei

Asahi Kasei’s Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar's API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time

TOKYO--(BUSINESS WIRE)--Peptistar has integrated Asahi Kasei’s novel forward osmosis–membrane distillation (FO–MD) system into its facility for trial production of APIs....

EAS Batteries Starts Sales of Ultra-High-Power Cell Using Asahi Kasei’s Novel Electrolyte Acetolyte™

DUSSELDORF, Germany--(BUSINESS WIRE)--EAS Batteries has commercialized its ultra-high-power lithium-ion LFP cell which incorporates Asahi Kasei’s novel Acetolyte™....

Asahi Kasei Life Science Acquires License for Novel Antibody-Drug Conjugate Technology from The Noguchi Institute – A Major Milestone for More Efficient and Safer Cancer Treatments

TOKYO--(BUSINESS WIRE)--Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute....
Back to Newsroom